WELLINGTON MANAGEMENT CO LLP 13D and 13G filings for Ascendis Pharma A/S:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-08 10:34 am Sale |
2024-09-30 | 13G | Ascendis Pharma A/S ASND |
WELLINGTON MANAGEMENT CO LLP | 1,261,480 2.210% |
-1,986,813 (-61.16%) |
Filing |
| 2024-02-08 10:03 am Purchase |
2023-12-29 | 13G | Ascendis Pharma A/S ASND |
WELLINGTON MANAGEMENT CO LLP | 3,248,293 5.770% |
172,281 (+5.60%) |
Filing |
| 2023-02-06 2:36 pm Sale |
2022-12-30 | 13G | Ascendis Pharma A/S ASND |
WELLINGTON MANAGEMENT CO LLP | 3,076,012 5.400% |
-992,464 (-24.39%) |
Filing |
| 2022-02-04 09:06 am Purchase |
2021-12-31 | 13G | Ascendis Pharma A/S ASND |
WELLINGTON MANAGEMENT CO LLP | 4,068,476 7.150% |
666,918 (+19.61%) |
Filing |
| 2021-02-03 10:29 am Purchase |
2020-12-31 | 13G | Ascendis Pharma A/S ASND |
WELLINGTON MANAGEMENT CO LLP | 3,401,558 6.450% |
3,401,558 (New Position) |
Filing |